| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 46 | 20.9x | 17.8x | Around median | |
Growth | 76 | 9.9% | 7.1% | Top tier | |
Quality | 88 | 20.9% | 4.5% | Top tier | |
Safety | 91 | — | 2.6x | Top tier | |
Capital Return | 72 | — | 2.12% | Top tier | |
Momentum | 29 | -21.3% | 2.9% | Bottom tier | |
Sentiment | 41 | 9 | 3 | Around median |
Estimates — analyst targets and a simplified DCF, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
ResMed operates in the digital health ecosystem for home care, focusing on treating sleep apnea and respiratory disorders through CPAP, APAP, bilevel devices, and life-support ventilators, alongside AirTouch and AirFit masks. AirSense 11 and AirCurve 11 devices connect patients and care providers to the MyAir and AirView platforms, while the residential care software business generates revenue from Brightree and Medifox DAN; the acquisition of Noctrix also added the Nydro device for treating restless legs syndrome to its sleep health portfolio.
In Q4 fiscal 2026, revenue reached $1.5 billion, up 9% as reported and 8% on a constant-currency basis, while adjusted earnings per share rose 16% to $2.95. Adjusted gross margin was 62.3%, up 90 basis points year over year, while adjusted operating margin was 35.2%, down 10 basis points; in the Americas, sleep devices grew 8% and masks and other products grew 10%, versus a 45% decline in life-support ventilators, while outside the Americas the same categories grew 13% and 12%, respectively, with life-support ventilators declining 38%.
For fiscal 2026, revenue increased 10% as reported and 8% on a constant-currency basis, adjusted earnings per share grew 17%, and the company generated $1.6 billion in free cash flow while expanding operating margin by 180 basis points. EDGAR data for the twelve months ended in fiscal 2026 show revenue of $5.5 billion, gross profit of $3.4 billion, net income of $1.5 billion, and earnings per share of approximately $10.43.
The analyst consensus on RMD is “Neutral,” with an average price target of $238.70 and a wide range between $213 and $300, reflecting meaningful divergence in estimates of the impact of sleep business growth versus the Astral crisis and slowing fiscal 2027 guidance. The average target is approximately 16% below the 52-week range high of $284.87 and approximately 32% above its low of $180.27, while the highest target exceeds the high by approximately 5%; the provided data did not include a reliable price-to-earnings ratio that could be used to confirm whether the stock is inexpensive or highly valued.
Figures in the text are as of 2026-08-28; the live price is shown at the top of the page.
Q4 fiscal 2026 revenue reached approximately $1.5 billion, up 9% as reported and 8% on a constant-currency basis. Sleep devices grew 8% in the Americas and 13% outside the Americas, while masks and other products increased 10% and 12%, respectively. This growth is supported by the expansion of AirSense 11, the launch of AirCurve 11 ST and ST-A, and the adoption of AirTouch and AirFit masks, while the expected price increase remained modest and volume was the main driver, according to management.
ResMed suspended new Astral sales throughout fiscal 2027 to direct electronic components toward the corrective action and serving existing patients. The company expects this to reduce revenue by approximately $75 million, equivalent to 130 basis points of growth, and to pressure earnings per share by approximately $0.15. In Q4 fiscal 2026, it recorded a $42 million provision to cover the expected costs of the global field action.
ResMed describes GLP-1 drugs as a supportive factor for its business based on an analysis of more than 2.5 million anonymized patients. Patients with PAP and GLP-1 prescriptions were approximately 11% more likely to initiate PAP therapy, more than 3% more likely to resupply after one year, and more than 6% more likely after three years. Data presented by the company in June 2026 also showed that more than 40% of newly diagnosed sleep apnea patients initiated PAP within 90 days of diagnosis, compared with less than 3% who initiated GLP-1.
Automated analysis for informational purposes only — not investment advice.
By the August 6, 2026 call, Oura had referred approximately 13 thousand users from its app to ResMed.com, and thousands of them completed a sleep assessment. Approximately 75% of those assessed reported that they had not been previously diagnosed, indicating the ability of wearable devices to direct new users toward screening and care. Within the therapy ecosystem, the AI-powered sleep coach in the MyAir app received more than 1.5 million inquiries and also helped reduce customer service inquiries.
ResMed announced the sale of MatrixCare on July 7, 2026, and expects the transaction to close around September 1, 2026, following regulatory approvals. MatrixCare generated approximately $220 million in revenue and $58 million in adjusted operating profit in fiscal 2026, and the sale is expected to dilute earnings per share by approximately $0.30 in fiscal 2027. In contrast, the company closed the acquisition of Noctrix on June 1, 2026, to add the Nydro device for treating restless legs syndrome, with an expected dilutive impact of $0.20 on earnings per share during fiscal 2027.
ResMed expects reported revenue between $5.75 billion and $5.85 billion and adjusted earnings per share between $12 and $12.25 in fiscal 2027. This represents reported earnings per share growth of approximately 7% to 10%, while underlying earnings per share growth is 12% to 14% after excluding the impact of the MatrixCare sale and the Noctrix acquisition. The plan also includes $1.5 billion in share repurchases, a 10% increase in the quarterly dividend to $0.66, and total returns of more than $1.85 billion to shareholders.
